← Library
Cerebrolysin
Research Use
Also known as FPF-1070
Function
Primary
Stroke recovery · Vascular & Alzheimer dementia (ex-US)
Mechanism
Porcine-brain-derived low-MW peptide mixture with BDNF/GDNF/NGF-like activity — promotes neurogenesis, synaptogenesis and neuroprotection.
Evidence
Clinical RCT (Limited)
Research
Phase III CARS, CASTA trials
Dosing
Range
10–50 mL/day IV (clinical); 5 mL/day IM (maintenance)
Frequency
Daily courses (10–21 days)
Route
Intravenous · Intramuscular
Cycling
10–21 day courses, repeated quarterly.
Benefits
- ·Improved post-stroke motor recovery
- ·Cognitive improvement in dementia
- ·Neuroprotective
Risks
- ·Allergic reaction (porcine origin)
- ·Vertigo, agitation
- ·Injection-site reactions
Contraindications
- ·Severe renal impairment
- ·Status epilepticus
- ·Allergy to porcine peptides
Regulatory
Approved in ~50 countries; not FDA-approved
Functional Groups
Cited Works
- Muresanu DF et al. Cerebrolysin in Acute Ischemic Stroke (CARS). Stroke. 2016;47:151.source